{"": [106, 1684, 0], "1. Introduction": [1685, 6362, 0], "2.1. Expression of Proteins and Antibodies": [6389, 7325, 0], "2.2. ELISA": [7326, 8004, 0], "2.3. Binding to Recombinant Fc\u03b3Rs": [8005, 8812, 0], "2.4.1. Complement Binding": [8850, 9762, 0], "2.4.2. Affinity to Human FcRn": [9763, 10488, 0], "2.4. Biolayer Interferometry Assays": [8813, 10488, 1], "2.5. CD107a Degranulation Assay": [10489, 11738, 0], "2.6. FC\u03b3 Receptor Potency Assay": [11739, 13267, 0], "2.7. Plaque Reduction Neutralization Test (PRNT)": [13268, 13821, 0], "2.8. Animal Experiments": [13822, 15772, 0], "2.9. Measurement of Viral RNA by qRT-PCR": [15773, 16825, 0], "2.10. Lung Histology": [16826, 17238, 0], "2. Materials and Methods": [6363, 17238, 1], "3.1. Construction of Fc-Engineered Antibodies": [17251, 23796, 0], "3.2. Prophylactic Activity of MD65-AG In-Vivo": [23797, 28026, 0], "3.3. Fc-Independent Post-Exposure Protection of SARS-CoV-2 Infected Mice": [28027, 31386, 0], "3.4. Dose-Dependent Therapeutic Efficacy of MD65-AG": [31387, 33749, 0], "3.5. Fc-Independent Post-Exposure Protection by Anti-NTD Antibody": [33750, 35968, 0], "3. Results": [17239, 35968, 1], "4. Discussion": [35969, 43315, 0]}